Inovio Pharmaceuticals Inc (INO)

[Lakers_w]

"Trying to stop omicron is kind of like trying to stop the wind," he told CNBC's "Squawk Box Asia."

China is "uniquely at risk" to omicron, Osterholm said, for a combination of reasons: Early studies suggest its Sinovac and Sinopharm vaccines are "not very effective" against the variant, and at the same time China's success at preventing the spread of Covid so far means it has a very large population that remains vulnerable.

According to U.S.-based consultancy Eurasia Group, China's zero-Covid policy ranks among the top risks for 2022.

While the approach "looked incredibly successful in 2020," it has now "become a fight against a much more transmissible variant with broader lockdowns and vaccines with limited effectiveness,"
https://news.google.com/articles/CAIiEFfonXmF9eDW6sbyARYHIw0qGQgEKhAIACoHCAow2Nb3CjDivdcCMJ_d7gU?hl=en-US&gl=US&ceid=US%3Aen